Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

memantine-donepezil

memantine-donepezil
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Namzaric CAPSULE, EXTENDED RELEASE, ORAL 14 mg-10 mg, 28 mg-10 mg    
Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

memantine-donepezil (Namzaric)

  • 7 mg-10 mg extended release capsule once daily
  • 14 mg-10 mg extended release capsule once Daily
  • 21 mg-10 mg extended release capsule once Daily                                                           
  • 28 mg-10 mg extended release capsule once Daily

memantine (Namenda) AND donepezil (Aricept)

  • ONE 5 mg memantine tablet PLUS ONE 10 mg donepezil tablet once Daily
  • ONE 10 mg memantine tablet PLUS ONE 10 mg donepezil tablet once Daily
  • ONE 5 mg memantine tablet qAM, ONE memantine 10 mg tablet qPM, and ONE 10 mg donepezil tablet once Daily
  • ONE 10 mg memantine tablet BID PLUS ONE 10 mg donepezil tablet once Daily

Namzaric is classified as non-formulary, not stocked. It should be interchanged to the individual components dispensed separately.

Reviewed: 23 June 2015 (Namzaric), and 24 July 2018 (7 mg-10 mg and 21 mg-10 mg)

Last updated: Jul. 25, 2018






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved